Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winer

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Clinical Breast Cancer|July 25, 2008
Perceptions and management approaches of physicians who care for women with ductal carcinoma in situAnn Partridge, Jeffrey P Winer, Mehra Golshan, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
The Breast Journal|October 25, 2011
Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?Christina Barkley, Harold Burstein, Barbara Smith, et al.
Cancer|August 25, 2005
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066Jeffrey Peppercorn, James Herndon, Alice B Kornblith, et al.
Annals of Surgery|July 30, 2015
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907Alice B Kornblith, Lan Lan, Laura Archer, et al.
Journal of the National Cancer Institute|February 14, 2008
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort studyAnn Partridge, Kristie Adloff, Emily Blood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancerAman Buzdar, Joyce A O'Shaughnessy, Daniel J Booser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.
Journal of Surgical Oncology|July 21, 2007
Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?Davendra Segara, Ian E Krop, Judy E Garber, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Clinical Breast Cancer|July 25, 2008
Perceptions and management approaches of physicians who care for women with ductal carcinoma in situAnn Partridge, Jeffrey P Winer, Mehra Golshan, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
The Breast Journal|October 25, 2011
Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates?Christina Barkley, Harold Burstein, Barbara Smith, et al.
Cancer|August 25, 2005
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066Jeffrey Peppercorn, James Herndon, Alice B Kornblith, et al.
Annals of Surgery|July 30, 2015
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2011
Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907Alice B Kornblith, Lan Lan, Laura Archer, et al.
Journal of the National Cancer Institute|February 14, 2008
Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort studyAnn Partridge, Kristie Adloff, Emily Blood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancerAman Buzdar, Joyce A O'Shaughnessy, Daniel J Booser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrheaChau Dang, Nancy Lin, Beverly Moy, et al.
Journal of Surgical Oncology|July 21, 2007
Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?Davendra Segara, Ian E Krop, Judy E Garber, et al.
Pageof 11